Clinical trials: Metastatic or Locally Advanced Unresectable Solid Tumors
- Condition Metastatic or Locally Advanced Unresectable Solid Tumors
- Funder type Industry (pharma, biotech, devices)
Locally Advanced or Metastatic Solid Tumors
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
This is an early development study of ASP388B in people with solid tumors. In this study, ASP388B will be given to people for the first time. It will be given by itself or together with standard cancer therapies.
- Trial name
- NCT07730021
- Testing
- ASP388B, Pembrolizumab, Carboplatin
- Where
- 4 sites in United States, Japan
- Volunteers
- 392 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Solid Tumor
A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
This is an open-label, multicenter, dose escalation and expansion phase I /II study of IBI3004 in subjects with unresectable, locally advanced or metastatic solid tumors.
- Trial name
- NCT06198426
- Testing
- IBI3004
- Where
- 5 sites in Australia, China
- Volunteers
- 5 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Solid Tumor, Adult, Head and Neck Cancer
PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL
The purpose of this first-in-human study of CX-2029 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2029 in adult subjects with metastatic or locally advanced…
- Conditions
- Solid Tumor, Adult, Head and Neck Cancer, Non Small Cell Lung Cancer, Diffuse Large B Cell Lymphoma
- Trial name
- NCT03543813
- Testing
- CX-2029
- Where
- 25 sites in United States, South Korea and 2 more
- Volunteers
- 133 people
- Sponsor
- CytomX Therapeutics
Solid Tumor
A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
This is a phase 1/2 multicenter, open-label, first-in-human study of IBI130. It includes a phase 1 dose escalation and expansion section to identify MTD/RP2D of IBI130, plan to enroll 20~182 subjects,and a phase 2 to explore…
- Trial name
- NCT05923008
- Testing
- IBI130
- Where
- Australia
- Volunteers
- 182 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Solid Tumor, Adult, Breast Cancer
PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors
The purpose of this first-in-human study of CX-2009 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2009 in adult subjects with metastatic or locally advanced…
- Conditions
- Solid Tumor, Adult, Breast Cancer, Non Small Cell Lung Cancer, Head and Neck Cancer
- Trial name
- NCT03149549
- Testing
- CX-2009
- Where
- 26 sites in United States, Netherlands and 2 more
- Volunteers
- 99 people
- Sponsor
- CytomX Therapeutics
Head and Neck Cancer, Cervical Cancer
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous T cells are engineered to express a T cell receptor that recognizes tumor-associated antigens presented on specific Human…
- Conditions
- Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, HPV16 Related Cancers
- Trial name
- NCT05812027
- Testing
- Tumor and HLA Profiling
- Where
- 21 sites in United States
- Volunteers
- 1,150 people
- Sponsor
- TScan Therapeutics, Inc.
Solid Tumours
A Study of AP601 in Patients With Locally Unresectable Advanced or Metastatic Solid Tumors
A Phase 1, Open-Label Study of the Safety, Tolerability,Pharmacokinetics, Pharmacodynamics and Clinical Activity of AP601 in Patients with Solid Tumours.The study is designed to find the highest dose of AP601 that can be given…
- Trial name
- NCT07165067
- Testing
- AP601
- Where
- 3 sites in Australia
- Volunteers
- 36 people
- Sponsor
- AP Biosciences Inc.
Melanoma, Urothelial Carcinoma
A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
Safety study of RC198 in Subjects with Solid Tumors.
- Conditions
- Melanoma, Urothelial Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT05867303
- Testing
- RC198 Injection
- Where
- 5 sites in Australia, China
- Volunteers
- 48 people
- Sponsor
- RemeGen Co., Ltd.
Solid Tumor, Metastatic Tumor
A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors
A Phase 1 dose escalation study to determine if axatilimab as monotherapy and axatilimab in combination with a fixed dose of durvalumab will be sufficiently safe and well-tolerated at biologically active doses to warrant further…
- Conditions
- Solid Tumor, Metastatic Tumor, Locally Advanced Malignant Neoplasm, Unresectable Malignant Neoplasm
- Trial name
- NCT03238027
- Testing
- Axatilimab, Durvalumab
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- Syndax Pharmaceuticals
Unresectable or Metastatic Solid Tumors
INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
The purpose of this study is to determine the safety, preliminary evidence of clinical activity, and recommended Phase 2 dose (RP2D) of INCMGA00012 in combination with other agents that may improve the therapeutic efficacy of…
- Trial name
- NCT03589651
- Testing
- Retifanlimab, Epacadostat, INCB050465
- Where
- 9 sites in United States
- Volunteers
- 83 people
- Sponsor
- Incyte Corporation
Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors.
- Trial name
- NCT07488676
- Testing
- ASP546C
- Where
- 21 sites in United States, Japan
- Volunteers
- 150 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Head and Neck Cancer, Malignant Melanoma
GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
The purpose of this study is to measure safety, tolerability, and preliminary antitumor efficacy of GM103 administered alone and in combination with pembrolizumab in patients with locally advanced, unresectable, refractory and/or…
- Conditions
- Head and Neck Cancer, Malignant Melanoma, Colorectal Cancer, Renal Cell Carcinoma
- Trial name
- NCT06265025
- Testing
- GM103 (Part A), GM103 (Part B), GM103 and Pembrolizumab (Part C)
- Where
- 4 sites in South Korea
- Volunteers
- 125 people
- Sponsor
- GeneMedicine Co., Ltd.
Locally Advanced (Unresectable) or Metastatic Solid Tumors
SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors
This study was an open-label phase Ⅱ study to evaluate the safety and efficacy of SSGJ-705 Plus SSGJ-612 ± Chemotherapy in patients with advanced HER2-Expressing Solid Tumors.
- Trial name
- NCT07646626
- Testing
- SSGJ-705, SSGJ-612, SSGJ-705 combined with chemotherapy
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Solid Tumors
A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors
The primary objective is to evaluate the safety and tolerability of RC288; determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of RC288; and determine the recommended phase 2 dose (RP2D), and assess…
- Trial name
- NCT07537881
- Testing
- RC288 For Injection
- Where
- 14 sites in China
- Volunteers
- 326 people
- Sponsor
- RemeGen Co., Ltd.
Solid Tumor
HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors
A phase Ib, dose escalation, multiple dose trial with HuMax-IL8 in patients with metastatic or unresectable, locally advanced malignant solid tumors.
- Trial name
- NCT02536469
- Testing
- HuMax-IL8
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Bristol-Myers Squibb
Solid Tumor, Adult, Colorectal Cancer
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer
- Trial name
- EVEREST-2 (NCT06051695)
- Testing
- A2B694, A2B543, xT CDx with HLA-LOH Assay
- Where
- 12 sites in United States
- Volunteers
- 474 people
- Sponsor
- A2 Biotherapeutics Inc.
MSI-H/dMMR Solid Tumor
A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid Tumors
It is a single-arm, open-label, multicenter, phase II study to evaluate the safety, efficacy, pharmacokinetics (PK) and immunogenicity of AK104 as a single agent in subjects with previously-treated locally advanced unresectable…
- Trial name
- NCT04547101
- Testing
- AK104
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Akeso
Solid Tumor, RAS Mutation
Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
This is a phase I study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of ASKC189 in in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
- Trial name
- NCT07836036
- Testing
- ASKC189
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Unresectable Locally Advanced or Metastatic Solid Tumors
IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
This is a phase 1/2 multicenter, multi-regional, open-label, first-in-human study of IBI3014 in participants with unresectable locally advanced or metastatic solid tumors.
- Trial name
- NCT06974812
- Testing
- IBI3014
- Where
- 3 sites in China
- Volunteers
- 250 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
This is a nonrandomized, uncontrolled, open-label, multicenter Phase 2 study to evaluate the efficacy, safety, and tolerability of futibatinib in combination with PD-1 antibody-based SoC therapy in adult patients with solid…
- Conditions
- Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Siewert Type 1 GEJ Cancer
- Trial name
- NCT05945823
- Testing
- Futibatinib, Pembrolizumab, Cisplatin
- Where
- 22 sites in United States, France and 2 more
- Volunteers
- 53 people
- Sponsor
- Taiho Oncology, Inc.